Openbookopenbook
Equity
Opus Genetics, Inc.(IRD)
USD --+0.00%
Reward60Moderate
Risk34Moderate
📊75%Data
Revenue down 20% YoY
IRD
+0.0 · +0.00%
USD · NASDAQ
Opus Genetics, Inc. | Healthcare
Profitless Growth
Market Cap:241.37M
ℹ️
Reward Rating
60
Moderate
Top 50% (model universe)
75% data coverage
ℹ️
Risk Rating
34
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on IRD to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $7.75.

What is Opus Genetics, Inc.?

, a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs).

IRD · Verdict

Solid reward · moderate risk

IRD stands out on balance sheet and growth, but watch the cash flow signal.

Based on 88% data coverage

IRD · Verdict

What’s working & what to watch

Strengths 3

  • Balance sheet97/100

    Current ratio 3.24

  • Growth81/100

    Rev +165.2% CAGR · earnings +0.5%

  • Volatility80/100

    Top decile vs peers

Watchouts 2

  • Cash flow29/100

    -233% free-cash-flow margin

  • Profitability32/100

    -523% net margin · -339% ROE

Model-based scoring. For information only — not financial advice.

What is Opus Genetics, Inc.?

, a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs). It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 241.37M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (60)

The scoring profile indicates moderate reward potential, with growth and valuation as the leading contributors. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap241.37M
P/E RatioN/A
Dividend YieldN/A
52 Week High3.965
52 Week Low0.65
Last AnnualDecember
IPO Date5/23/2005
IncorporatedUSA
Shares Outstanding69M
No. of Employees18
IndustryBiotechnology
ExchangeNASDAQ
Beta0.593
CurrencyUSD
Websiteopusgtx.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.